Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

• Prif Awduron: Sakib Burza (Awdur), Prabhat K Sinha (Awdur), Raman Mahajan (Awdur), María Angeles Lima (Awdur), Gaurab Mitra (Awdur), Neena Verma (Awdur), Manica Balasegaram (Awdur), Pradeep Das (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Public Library of Science (PLoS), 2014-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

BACKGROUND: A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a pr...